Lead Candidate

A New Frontier in Bacterial Infections, Inflammatory, Metabolic & Infectious Disease

Longhorn Vaccines and Diagnostics is building a new class of anti-bacterial immunotherapies designed to target the conserved cell-wall structures that sit upstream of infection, sepsis, and chronic inflammation. Rather than chasing individual pathogens or downstream cytokines, Longhorn’s platform focuses on bacterial pattern-associated molecular patterns, including peptidoglycan and lipoteichoic acid, that are shared across clinically important organisms and capable of driving inflammatory pathology even after bacterial killing begins.

The lead program, LHNVD-501, is a humanized, extended-half-life monoclonal antibody derived from Longhorn’s anti-peptidoglycan work. It is designed to bind conserved peptidoglycan structures across Gram-positive, Gram-negative, and mycobacterial organisms, with the goal of both promoting immune clearance of bacteria and neutralizing circulating peptidoglycan fragments that activate innate immune pathways. This creates a dual opportunity: adjunctive therapy for serious bacterial infection and sepsis, and a broader strategy for reducing persistent bacterial-component-driven inflammation.

Longhorn’s second major asset, LHNVD-502, extends a clinically validated anti-lipoteichoic acid lineage originally developed by Longhorn leadership as pagibaximab. Now modified as a modern humanized, extended-half-life antibody, LHNVD-502 targets a key Gram-positive cell-wall inflammatory trigger with prior human safety and pharmacology precedent. In combination, LHNVD-501 and LHNVD-502 are designed to address the biology of Gram-positive sepsis more completely than either target alone, reflecting evidence that peptidoglycan and lipoteichoic acid can act together to amplify shock, cytokine release, nitric-oxide signaling, and multi-organ dysfunction.

The antibodies are intended to complement, not replace, standard-of-care antimicrobials: antibiotics expose and release bacterial cell-wall antigens, while antibodies can help opsonize bacteria, clear debris, and dampen the inflammatory consequences of bacterial breakdown. That combination could be especially valuable in high-risk settings such as ICU admission, neonatal sepsis prevention, antimicrobial-resistant infections, and other conditions where bacterial products continue to drive pathology.

Longhorn’s vision is to turn conserved bacterial cell-wall targets into a scalable therapeutic platform. By pairing broad-spectrum anti-peptidoglycan coverage with anti-lipoteichoic acid lineage validation, the company is advancing a biologic approach that could reduce infection severity, improve immune clearance, and interrupt the upstream inflammatory signals that underlie sepsis and bacterial-component-associated disease. The result is a platform with near-term infectious-disease applications and long-term potential across inflammation, aging, and chronic disease biology.

LHNVD-501 Recently Presented Data